Show simple item record

dc.contributor.authorLamarca, Angela
dc.contributor.authorRonot, M
dc.contributor.authorMoalla, S
dc.contributor.authorCrona, J
dc.contributor.authorOpalinska, M
dc.contributor.authorLopez, LC
dc.contributor.authorPezzutti, D
dc.contributor.authorNajran, Pavan
dc.contributor.authorCarvalho, LFDP
dc.contributor.authorBezerra, ROF
dc.contributor.authorBorg, Philip
dc.contributor.authorVietti, VN
dc.contributor.authorVidal, TH
dc.contributor.authorde Mestier, L
dc.contributor.authorSchaefer, N
dc.contributor.authorBaudin, E
dc.contributor.authorSundin, A
dc.contributor.authorCosta, FP
dc.contributor.authorPavel, M
dc.contributor.authorDromain, C
dc.date.accessioned2019-10-04T09:48:24Z
dc.date.available2019-10-04T09:48:24Z
dc.date.issued2019en
dc.identifier.citationLamarca A, Ronot M, Moalla S, Crona J, Opalinska M, Lopez Lopez C, et al. Tumour growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumours; the GREPONET-2 study. Clin Cancer Res. 2019 Aug 2.en
dc.identifier.pmid31375514en
dc.identifier.doi10.1158/1078-0432.CCR-19-0963en
dc.identifier.urihttp://hdl.handle.net/10541/622108
dc.description.abstractPURPOSE: TGR represents the percentage change in tumour volume per month (%/m). Previous results from the GREPONET study showed that TGR measured after 3 months (TGR3m) of starting systemic treatment (ST) or watch and wait (WW) was an early biomarker predicting progression-free survival (PFS) in NETs. EXPERIMENTAL DESIGN: Pts from7 centres with advanced grade(G) 1/2 NETs from the pancreas(P)/small bowel(SB) initiating ST/WW were eligible. Computed tomography (CT) / magnetic resonance imaging (MRI) performed at pre-baseline, baseline and 3(+/-1) months of study entry were retrospectively reviewed. Aim-1: explore treatment-induced changes in TGR (?TGR3m-BL) (paired T-test) and Aim-2: validate TGR3m (<0.8%/m vs ?0.8%/m) as an early biomarker in an independent cohort (Kaplan-Meier/Cox Regression). RESULTS: Out of 785 pts screened, 127 were eligible. Mean (SD) TGR0 and TGR3m were 5.4%/m (14.9) and -1.4%/m (11.8), respectively. Mean(SD) ?TGR3m-BL paired-difference was -6.8%/m(19.3) (p<0.001). Most marked ?TGR3m-BL (mean (SD);p) were identified with targeted therapies (-11.3%/m(4.7);0.0237) and chemotherapy (-7.9%/m(3.4);0.0261). Multivariable analysis confirmed the absence of previous treatment (Odds Ratio (OR) 4.65 (95%CI 1.31-16.52); p-value0.018) and low TGR3m (continuous variable; OR 1.09 (95%CI 1.01-1.19); p-value0.042) to be independent predictors of radiological objective response. When the multivariable Cox Regression was adjusted to grade (p-value 0.004) and stage (p-value0.017), TGR3m?0.8 (vs.<0.8) maintained its significance (p<0.001), while TGR0 and ?TGR3m-BL did not. TGR3m was confirmed as an independent prognosis factor for PFS (external validation; Aim-2) (multivariable HR 2.21 (95%CI 1.21-3.70); p-value0.003). CONCLUSIONS: TGR has a role as biomarker for monitoring response to therapy for early prediction of PFS and radiological objective response.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1158/1078-0432.CCR-19-0963en
dc.titleTumour growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumours; the GREPONET-2 studyen
dc.typeArticleen
dc.contributor.departmentMedical Oncology, The Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalClinical Cancer Researchen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record